- Size
- 10mg
- Purity
- 99.601%
- Formula
- C152H252N44O42
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone built on the GHRH(1-29) sequence — the shortest fragment of the native hormone that retains full activity at the GHRH receptor. Four amino-acid substitutions protect it against enzymatic degradation, principally cleavage by dipeptidyl peptidase-4, which limits the useful life of unmodified GHRH(1-29) to a few minutes.
This vial is the no-DAC form, also written as Modified GRF (1-29). It omits the drug affinity complex — the maleimide group that, in the DAC version, binds covalently to circulating albumin and stretches the half-life into days. Without that group the molecule clears far faster, so the GH signal it produces is a short pulse rather than a sustained elevation. The published DAC pharmacokinetics (a 5.8–8.1 day half-life, with plasma GH raised for six days or more after a single injection) describe the DAC construct and should not be read onto the no-DAC form.
Mechanistically the compound works upstream of the pituitary rather than replacing growth hormone itself: it prompts somatotrophs to release their own stores. Human work with the long-acting analogue reports that pulsatile GH secretion persists during continuous receptor stimulation, indicating that the underlying secretory rhythm is not abolished by sustained GHRH-receptor signalling. Because GHRH and ghrelin-receptor pathways are separate, GHRH analogues are commonly co-studied with GHS-R1a agonists such as ipamorelin.
Categorised as Hormones — GH secretagogues, recombinant GH and gonadotropins.For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.